Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events

by Awatif Hafiz, Alshaya Abdulrahman I, Katelyn W. Sylvester, Jean M. Connors, Jessica Rimsans
Published 2021-12-01

Heparin‐induced thrombocytopenia in end‐stage renal disease: Reliability of the PF4‐heparin ELISA

by Julie Kelly, Katelyn W. Sylvester, Jessica Rimsans, Thomas D. Bernier, Clara Ting, Jean M. Connors
Published 2021-07-01

Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support

by Amy A. Levesque PharmD, Andrea R. Lewin PharmD, Jessica Rimsans PharmD, Katelyn W. Sylvester PharmD, Lara Coakley NP, Frank Melanson RN, Hari Mallidi MD, Mandeep Mehra MD, Michael M. Givertz MD, Jean M. Connors MD
Published 2019-03-01

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy

by Kevin McLaughlin PharmD, BCPS, Jessica Rimsans PharmD, BCPS, Katelyn W. Sylvester PharmD, BCPS, CACP, John Fanikos Rph, MBA, David M. Dorfman MD, PhD, Patricia Senna MT, ASCP, Jean M. Connors MD, Samuel Z. Goldhaber MD
Published 2019-09-01